

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

REVISED VERSION

(19) World Intellectual Property
Organization
International Bureau(43) International Publication Date
5 August 2004 (05.08.2004)

PCT

(10) International Publication Number
WO 2004/064845 A1(51) International Patent Classification⁷: **A61K 31/675**,
31/513 // (A61K 31/675, 31:513)(21) International Application Number:
PCT/US2004/000832

(22) International Filing Date: 13 January 2004 (13.01.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/440,308 14 January 2003 (14.01.2003) US
60/440 246 14 January 2003 (14.01.2003) US(71) Applicant (for all designated States except US): **GILEAD SCIENCES, INC.** [US/US]; 333 Lakeside Drive, Foster City, CA 94404 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DAHL, Terrence, C.** [US/US]; 1646 Kennewick Drive, Sunnyvale, CA 94087 (US). **MENNING, Mark, M.** [US/US]; 2520 Lake Street, San Francisco, CA 94121 (US). **OLIVAI, Reza** [US/US]; 1262 Crestview Drive, San Carlos, CA 94070 (US).(74) Agents: **BOSSE, Mark, L., et al.**; Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the revised international search report: 23 September 2004

(15) Information about Correction:

see PCT Gazette No. 39/2004 of 23 September 2004, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY

(57) Abstract: The present invention relates to therapeutic combinations of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread[®]) and (2R, 5S, cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine, Emtriva[™], (-)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations.

WO 2004/064845 A1

INTERNATIONAL SEARCH REPORT

PCT/US2004/000832

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61K31/675 A61K31/513
 //(A61K31/675, 31:513)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
 EPO-Internal, BIOSIS, INSPEC, CHEM ABS Data, EMBASE, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>RISTIG MARIA B ET AL: "Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed." JOURNAL OF INFECTIOUS DISEASES, vol. 186, no. 12, 15 December 2002 (2002-12-15), pages 1844-1847, XP002284897 ISSN: 0022-1899 abstract page 1844, column 2, second last paragraph: "Subjects" page 1845, column 2, last paragraph before "Discussion"</p> <p style="text-align: center;">----- -/--</p>	1-58

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

18 June 2004

Date of mailing of the international search report

12/07/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Rodriguez-Palmero, M

INTERNATIONAL SEARCH REPORT

US2004/000832

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MURRY, JEFFREY P. ET AL: "Reversion of the M184V mutation in simian immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudine" JOURNAL OF VIROLOGY, 77(2), 1120-1130 CODEN: JOVIAM; ISSN: 0022-538X, 12 January 2003 (2003-01-12), XP002284898 page 1126, figure 2 page 1129, column 1, paragraph 2	1-58
X	"Anti-HIV drug updates--three drugs on the near horizon." PROJECT INFORM PERSPECTIVE. JAN 2003, no. 35, January 2003 (2003-01), pages 4-7, XP001181983 page 6, column 2, paragraph 3 - page 7, column 2, paragraph 3	1-58
Y	FUNG HORATIO B ET AL: "Tenofovir disoproxil fumarate: A nucleotide reverse transcriptase inhibitor for the treatment of HIV infection." CLINICAL THERAPEUTICS, vol. 24, no. 10, October 2002 (2002-10), pages 1515-1548, XP002285091 ISSN: 0149-2918 page 1533, column 1, paragraph 2 page 1542, table VIII	2, 3, 32, 33, 43-58
A		1, 4-31, 34-42
X	MULATO A S ET AL: "ANTI-HIV ACTIVITY OF ADEFOVIR (PMEA) AND PMPA IN COMBINATION WITH ANTIRETROVIRAL COMPOUNDS: IN VITRO ANALYSES" ANTIVIRAL RESEARCH, ELSEVIER SCIENCE BV., AMSTERDAM, NL, vol. 36, no. 2, November 1997 (1997-11), pages 91-97, XP000890091 ISSN: 0166-3542 page 93, column 2, paragraph 2 - page 95, column 1, paragraph 2 page 94, figure 1	1, 4-31, 34-42
Y		2, 3, 32, 33, 43-58
X	WO 00/25797 A (BARRY DAVID ; ROUSSEAU FRANCK (US); FURMAN PHILLIP A (US); PAINTER GEO) 11 May 2000 (2000-05-11) page 5, line 5-12 page 15, lines 1-24 claims 5, 10 and 20	25-31, 34-42
	-/--	

INTERNATIONAL SEARCH REPORT

PCT/US2004/000832

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>RICHMAN D D: "Antiretroviral activity of emtricitabine, a potent nucleoside reverse transcriptase inhibitor." ANTIVIRAL THERAPY. JUN 2001, vol. 6, no. 2, June 2001 (2001-06), pages 83-88, XP009032162 ISSN: 1359-6535</p>	<p>2,3,32, 33,43-58</p>
A	<p>page 84, column 2, second last paragraph - page 85, column 1, paragraph 2</p>	<p>1,4-31, 34-42</p>
A	<p>DE CLERCQ ERIK: "New anti-HIV agents and targets" MEDICINAL RESEARCH REVIEWS, vol. 22, no. 6, November 2002 (2002-11), pages 531-565, XP002284899 ISSN: 0198-6325 page 541, paragraph 3 - page 542, paragraph 5</p>	<p>1-58</p>

INTERNATIONAL SEARCH REPORT

PCT/US2004/000832

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0025797	A	11-05-2000	
		AU 1810600 A	22-05-2000
		CN 1329497 T	02-01-2002
		EP 1380303 A1	14-01-2004
		EP 1382343 A1	21-01-2004
		EP 1124562 A1	22-08-2001
		ID 29471 A	30-08-2001
		JP 2002528508 T	03-09-2002
		WO 0025797 A1	11-05-2000
		US 2003158150 A1	21-08-2003
		US 6528515 B1	04-03-2003